Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | USP5 | P45974 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874757 | 0.88 | PTGS1 (0.34) | NPC1POLBRAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL4871561 | 0.87 | ALDH1A1 (0.32) | RAB9ASMN1; SMN2GRIK1GRIK2 | |
| SCHEMBL4869170 | 0.83 | RAB9A (0.34) | NPC1POLBRAB9ASMN1; SMN2GRIK1 | |
| SCHEMBL4869162 | 0.83 | RAB9A (0.34) | NPC1POLBRAB9ASMN1; SMN2GRIK1 | |
| SCHEMBL4874130 | 0.81 | KMT2A (0.31) | — | |
| SCHEMBL4874754 | 0.71 | PTGS1 (0.34) | NPC1POLBRAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL4874766 | 0.71 | PTGS1 (0.34) | NPC1POLBRAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL4871572 | 0.70 | ALDH1A1 (0.32) | NPC1RAB9ASMN1; SMN2GRIK1GRIK2 | |
| SCHEMBL4871554 | 0.70 | ALDH1A1 (0.32) | NPC1RAB9ASMN1; SMN2GRIK1GRIK2 | |
| SCHEMBL4869159 | 0.69 | GRIK1 (0.38) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | NPC1 4695/4885POLB 3981/4885RAB9A 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.